10-Q: Cingulate Files CTx-1301 NDA Amid Leadership Turmoil

Cingulate Inc. reported increased net losses and a going concern warning, while successfully submitting its lead ADHD drug NDA and undergoing significant management restructuring.

Summary

• Cingulate Inc. is a biopharmaceutical company focused on developing once-daily, multi-dose therapies using its Precision Timed Release (PTRTM) drug delivery platform, with an initial focus on ADHD and anxiety.
• The company reported a net loss of $4.8 million for the three months ended June 30, 2025, an increase from $3.2 million for the same period in 2024.
• For the six months ended June 30, 2025, the net loss was $8.6 million, up from $6.2 million in the prior year period.
• Research and development expenses increased by 33.5% to $4.9 million for the six months ended June 30, 2025, driven by clinical operations and regulatory costs for CTx-1301 NDA submission.
• General and administrative expenses rose by 39.2% to $3.4 million for the six months ended June 30, 2025, primarily due to increased legal and professional fees.
• As of June 30, 2025, cash and cash equivalents stood at $8.9 million, down from $12.2 million at December 31, 2024.
• The company has an accumulated deficit of $117.1 million as of June 30, 2025.
• Management expressed substantial doubt about the company's ability to continue as a going concern within one year.
• The New Drug Application (NDA) for CTx-1301, a lead ADHD product candidate, was submitted to the FDA on July 31, 2025, following a PDUFA fee waiver received on July 29, 2025.
• Clinical development for CTx-1302 (ADHD) is pending additional capital, and CTx-2103 (anxiety) development continues with a 505(b)(2) pathway identified.
• The company entered a master services agreement with Indegene, Inc. for CTx-1301 commercialization in the United States.
• Significant management changes occurred in August 2025, including the termination of the EVP & COO, the CEO being placed on administrative leave due to personal legal proceedings, and the appointment of an interim CEO and Executive Chairman.

Sentiment

Score: 3

Explanation: The sentiment is largely negative due to significant financial distress, including increased losses, declining cash, and a going concern warning. The severe management instability, with the CEO on administrative leave due to legal charges, further exacerbates concerns. While the NDA submission for CTx-1301 is a positive clinical milestone, it is overshadowed by the operational and financial challenges.

Positives

• Submitted the New Drug Application (NDA) for CTx-1301 to the FDA on July 31, 2025, a major regulatory milestone.
• Received a PDUFA fee waiver from the FDA for the CTx-1301 NDA on July 29, 2025.
• Completed food effect studies for CTx-1301, demonstrating it can be taken with or without food.
• Safety data from CTx-1301 Phase 3 trials showed no serious treatment emergent adverse events (TEAEs) or TEAEs leading to death.
• Identified a streamlined 505(b)(2) regulatory pathway for CTx-2103 (anxiety), potentially reducing development time and resources.
• Entered a master services agreement with Indegene, Inc. for commercialization of CTx-1301 in the United States, leveraging their comprehensive infrastructure.
• Net cash used in operating activities decreased to $9.4 million for the six months ended June 30, 2025, from $10.5 million in the prior year period.

Negatives

• Incurred a net loss of $4.8 million for the three months ended June 30, 2025, a 49.2% increase from $3.2 million in the prior year period.
• Reported a net loss of $8.6 million for the six months ended June 30, 2025, a 39.0% increase from $6.2 million in the prior year period.
• Accumulated deficit reached $117.1 million as of June 30, 2025.
• Cash and cash equivalents decreased to $8.9 million as of June 30, 2025, from $12.2 million at December 31, 2024.
• Substantial doubt exists about the company's ability to continue as a going concern within one year.
• Current liabilities increased to $6.7 million as of June 30, 2025, from $5.0 million at December 31, 2024, primarily due to an increase in the current portion of the note payable.
• Net cash provided by financing activities significantly decreased to $6.1 million for the six months ended June 30, 2025, from $11.0 million in the prior year period.
• The Chairman and Chief Executive Officer was placed on administrative leave due to personal legal proceedings, indicating significant management instability.
• The employment of the former Executive Vice President and Chief Operating Officer was terminated in August 2025.

Risks

• Substantial doubt about the ability to continue as a going concern due to recurring losses and negative cash flows.
• Dependence on raising additional capital, which may not be available on acceptable terms or at all, potentially leading to delays or discontinuation of product development.
• Ability to maintain compliance with Nasdaq listing requirements, particularly concerning corporate governance and independent directors.
• Lack of operating history and no current revenue generation, making future profitability uncertain.
• Uncertainty regarding the timing and success of clinical trials for product candidates (CTx-1302, CTx-2103).
• Risk of not obtaining or maintaining regulatory approvals for product candidates (CTx-1301, CTx-1302, CTx-2103).
• Challenges in commercializing product candidates, including marketing, sales, and manufacturing capabilities.
• Intense competition within the pharmaceutical industry, potentially impacting market share and pricing.
• Difficulty in attracting and retaining key management and scientific personnel, exacerbated by recent leadership changes and departures.
• Potential for intellectual property disputes, including patent infringement actions by third parties.
• Exposure to restrictive covenants and potential events of default under the unsecured promissory note with Streeterville Capital, LLC, which could trigger increased interest rates or immediate repayment obligations.
• The contingent bonus plan for employees, estimated at $722,824, may become due, adding to financial obligations.

Future Outlook

The company expects to continue incurring significant expenses and operating losses in the near term as it seeks regulatory approval for CTx-1301, continues research and development for existing and new product candidates, advances manufacturing and commercialization efforts, and operates as a public company. Current cash is expected to satisfy capital needs into late 2025, but approximately $1.5 million of additional capital is required to advance CTx-1301 commercialization into early 2026, with further capital needed for other programs. Future funding strategies include equity offerings, debt, collaborations, or other strategic transactions.

Management Comments

• Management is evaluating various strategies to obtain additional funding, which may include additional offerings of equity, issuance of debt, or other capital sources, including potential collaborations with other companies or other strategic transactions.
• We believe our cash will satisfy our capital needs into late 2025 under our current business plan.
• To advance our commercialization efforts for CTx-1301 into early 2026, we will need to raise approximately $1.5 million of additional capital.
• We will also need additional capital to advance our other programs.
• We continue to negotiate potential international licensing agreements while remaining open to a strategic partnership in the United States.

Industry Context

Cingulate operates in the highly competitive biopharmaceutical industry, specifically targeting the Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety markets. The company's strategy of utilizing a proprietary drug delivery platform for once-daily, multi-dose therapies addresses a perceived unmet need for improved patient adherence and outcomes. The pursuit of the 505(b)(2) regulatory pathway for CTx-1301 and CTx-2103 is a common industry approach for drug development, allowing for a potentially faster and less resource-intensive approval process by relying on existing safety and efficacy data of previously approved drugs. The partnership with Indegene for commercialization reflects a trend among smaller biopharma companies to outsource commercial infrastructure to specialized firms.

Comparison to Industry Standards

• As a pre-revenue biopharmaceutical company, Cingulate's financial performance, characterized by significant operating losses and reliance on capital raises, is typical for its stage of development, similar to other clinical-stage biotechs that require substantial investment in R&D before commercialization.
• The company's use of the 505(b)(2) regulatory pathway for CTx-1301 and CTx-2103 aligns with industry best practices for accelerating drug approval by leveraging existing data, a strategy employed by companies like Supernus Pharmaceuticals (for ADHD drugs) or Jazz Pharmaceuticals (for sleep disorders) in their development of new formulations of existing compounds.
• The substantial doubt about the company's ability to continue as a going concern and the recent significant management instability, including the CEO's administrative leave due to personal legal proceedings, are notable deviations from the operational stability typically sought by mature industry players and can significantly impact investor confidence compared to peers with stable leadership and clear financial runways.

Management Changes

Corporate Governance

Legal Proceedings

• The Chairman and Chief Executive Officer, Shane Schaffer, was charged with one count of aggravated domestic battery on August 9, 2025, leading to his administrative leave.
• The company may, from time to time, be subject to legal proceedings and claims arising in the ordinary course of business; however, no accruals for material loss contingencies were recorded as of June 30, 2025.

Related Party Transactions

• In the first quarter of 2024, pre-funded warrants and capital contributions were issued in connection with the conversion of a related party note payable from Werth Family Investment Associates LLC (WFIA) into equity.

Stakeholder Impact

• Shareholders face significant dilution risk from ongoing and future equity capital raises (ATM, Lincoln Park agreements) and potential conversion of debt to equity.
• Shareholders are exposed to substantial share price volatility due to the company's pre-revenue status, high burn rate, going concern warning, and recent management instability.
• Employees who experienced salary reductions in December 2023 are eligible for a contingent bonus plan (estimated $722,824) upon NDA filing for CTx-1301, which occurred on July 31, 2025, potentially boosting morale but also representing a future cash or equity outflow.
• Creditors, particularly Streeterville Capital, LLC, are subject to the company's liquidity challenges and the terms of the promissory note, including potential redemption rights and increased interest rates upon default.
• Customers (future) may benefit from the potential approval and commercialization of CTx-1301 for ADHD, addressing an unmet need for once-daily stimulant medications.

Next Steps

• Advance commercialization efforts for CTx-1301 in the United States through the partnership with Indegene, Inc.
• Negotiate potential international licensing agreements for CTx-1301.
• Seek additional capital resources to initiate the clinical plan for CTx-1302 (dextroamphetamine) for ADHD.
• Continue development of CTx-2103 (buspirone) for anxiety, leveraging the 505(b)(2) pathway.
• Evaluate the potential impact of the One Big Beautiful Bill Act (OBBBA) on deferred tax balances and financial statements, to be reflected in the third quarter 10-Q.

Key Dates

Recommendation

Despite the significant clinical milestone of submitting the CTx-1301 NDA, the company faces severe financial instability, evidenced by increased net losses, declining cash reserves, and an explicit 'going concern' warning. The recent and ongoing management turmoil, including the CEO's administrative leave due to legal charges, introduces substantial operational and reputational risk. The continuous reliance on dilutive equity raises and the high burn rate without a clear path to profitability make the investment highly speculative. The combination of financial distress, governance issues, and the need for substantial additional capital in the near term presents an exceptionally high-risk profile, outweighing the clinical progress for a seasoned investor.

Keywords

Biopharmaceutical, ADHD, Anxiety, Drug Development, Clinical Trials, SEC Filing, 10-Q, Cingulate, CTx-1301, CTx-1302, CTx-2103, Nasdaq, Going Concern, Capital Raise, Management Change, FDA NDA